Skip to main content
SpringerLink
Log in

Depression und neurologische Erkrankungen

Depression and neurological diseases

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Bei vielen neurologischen Erkrankungen ist ein depressives Syndrom charakteristisches Merkmal der Primärerkrankung oder als Komorbidität von Bedeutung. Die Post-Stroke-Depression ist beispielsweise eine häufige und relevante psychiatrische Komplikation nach einem ischämischen Hirninfarkt. Etwa 4 von 10 Schlaganfallpatienten entwickeln im Verlauf ihrer Erkrankung eine depressive Störung, die sich ungünstig auf Verlauf und Prognose auswirkt. Umgekehrt ist eine Depression jedoch auch als Risikofaktor für bestimmte neurologische Erkrankungen zu werten. So wurde kürzlich in einer Metaanalyse prospektiver Kohortenstudien ein deutlich erhöhtes Schlaganfallrisiko für depressive Patienten nachgewiesen. Ferner spielt die Depression bei weiteren neurologischen Erkrankungen eine wichtige Rolle bezüglich Verlauf und Lebensqualität, etwa beim Morbus Parkinson, der Multiplen Sklerose oder der Epilepsie. Der Artikel möchte eine Übersicht geben über die wichtigsten epidemiologischen, pathophysiologischen und therapeutischen Aspekte depressiver Störungen als Komorbidität neurologischer Erkrankungen bzw. als Risikofaktor für neurologische Erkrankungen.

Summary

In many neurological diseases a depressive syndrome is a characteristic sign of the primary disease or is an important comorbidity. Post-stroke depression, for example, is a common and relevant complication following ischemic brain infarction. Approximately 4 out of every 10 stroke patients develop depressive disorders in the course of the disease which have a disadvantageous effect on the course and the prognosis. On the other hand depression is also a risk factor for certain neurological diseases as was recently demonstrated in a meta-analysis of prospective cohort studies which revealed a much higher stroke risk for depressive patients. Furthermore, depression plays an important role in other neurological diseases with respect to the course and quality of life, such as Parkinson’s disease, multiple sclerosis and epilepsy. This article gives a review of the most important epidemiological, pathophysiological and therapeutic aspects of depressive disorders as a comorbidity of neurological diseases and as a risk factor for neurological diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Goldstein LB, Bushnell CD, Adams RJ et al (2011) Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:517–584

    PubMed  Google Scholar 

  2. Loubinoux I, Kronenberg G, Endres M et al (2012) Poststroke depression: mechanisms, translation and therapy. J Cell Mol Med. DOI 10.1111/j.1582-4934.2012.01555.x

  3. Whyte EM, Mulsant BH (2002) Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 52:253–264

    PubMed  Google Scholar 

  4. Kronenberg G, Katchanov J, Endres M (2006) Post-stroke depression: clinical aspects, epidemiology, therapy, and pathophysiology. Nervenarzt 77:1176, 1179–1182, 1184–1185

    PubMed  CAS  Google Scholar 

  5. Heuschmann PU, Busse O, Wagner M et al (2010) Schlaganfallhäufigkeit und Versorgung von Schlaganfallpatienten in Deutschland. Für das Kompetenznetz Schlaganfall, die Deutsche Schlaganfall Gesellschaft sowie die Stiftung Deutsche Schlaganfall-Hilfe. Akt Neurol 37:333–340

    Google Scholar 

  6. Folstein MF, Maiberger R, McHugh PR (1977) Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 40:1018–1020

    PubMed  CAS  Google Scholar 

  7. Kronenberg G, Balkaya M, Prinz V et al (2012) Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry [Epub ahead of print]

  8. Robinson RG, Spalletta G (2010) Poststroke depression: a review. Can J Psychiatry 55:341–349

    PubMed  Google Scholar 

  9. Huff W, Steckel R, Sitzer M (2003) Poststroke depression: risk factors and effects on the course of the stroke. Nervenarzt 74:104–114

    PubMed  CAS  Google Scholar 

  10. Morris PL, Robinson RG, Andrzejewski P et al (1993) Association of depression with 10-year poststroke mortality. Am J Psychiatry 150:124–129

    PubMed  CAS  Google Scholar 

  11. Carson AJ, MacHale S, Allen K et al (2000) Depression after stroke and lesion location: a systematic review. Lancet 356:122–126

    PubMed  CAS  Google Scholar 

  12. Hackett ML, Anderson CS, House AO (2005) Management of depression after stroke: a systematic review of pharmacological therapies. Stroke 36:1098–1103

    PubMed  Google Scholar 

  13. Boden-Albala B, Litwak E, Elkind MS et al (2005) Social isolation and outcomes post stroke. Neurology 64:1888–1892

    PubMed  CAS  Google Scholar 

  14. Hackett ML, Anderson CS, House A, Xia J (2008) Interventions for treating depression after stroke. Cochrane Database Syst Rev 4:CD003437

    PubMed  Google Scholar 

  15. Härter M, Klesse C, Bermejo I et al (2010) Evidence-based therapy of depression: S3 guidelines on unipolar depression. Nervenarzt 81:1049–1068

    PubMed  Google Scholar 

  16. Marcum ZA, Vande Griend JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264–271

    PubMed  Google Scholar 

  17. Robinson RG, Jorge RE, Moser DJ et al (2008) Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 299:2391–2400

    PubMed  CAS  Google Scholar 

  18. Chollet F, Tardy J, Albucher JF et al (2011) Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 10:123–130

    PubMed  CAS  Google Scholar 

  19. Dam M, Tonin P, De Boni A et al (1996) Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 27:1211–1214

    PubMed  CAS  Google Scholar 

  20. Pariente J, Loubinoux I, Carel C et al (2001) Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 50:718–729

    PubMed  CAS  Google Scholar 

  21. Zittel S, Weiller C, Liepert J (2008) Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 22:3

    Google Scholar 

  22. Strubel T, Birkhofer A, Mössmer G, Förstl H (2010) SSRI – treatment and bleeding. What risks do we take? Nervenarzt 81:549–555

    PubMed  CAS  Google Scholar 

  23. Niedermaier N, Bohrer E, Schulte K et al (2004) Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry 65:1619–1623

    PubMed  CAS  Google Scholar 

  24. Neu P (2009) Correlation of depression with stroke. Pathophysiological mechanisms. Nervenarzt 80:772, 774–776, 778–780

    PubMed  CAS  Google Scholar 

  25. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442

    PubMed  Google Scholar 

  26. Pan A, Sun Q, Okereke OI et al (2011) Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 306:1241–1249

    PubMed  CAS  Google Scholar 

  27. Dong JY, Zhang YH, Tong J, Qin LQ (2012) Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 43:32–37

    PubMed  Google Scholar 

  28. O’Donnell MJ, Xavier D, Liu L, Zhang H et al (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376:112–123

    Google Scholar 

  29. Whooley MA (2006) Depression and cardiovascular disease: healing the broken-hearted. JAMA 295:2874–2881

    PubMed  CAS  Google Scholar 

  30. Holsboer F, Ising M (2010) Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81–109, C1–11

    PubMed  Google Scholar 

  31. Lederbogen F, Baranyai R, Gilles M et al (2004) Effect of mental and physical stress on platelet activation markers in depressed patients and healthy subjects: a pilot study. Psychiatry Res 127:55–64

    PubMed  CAS  Google Scholar 

  32. Duivis HE, Jonge P de, Penninx BW et al (2011) Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 168:913–920

    PubMed  Google Scholar 

  33. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741

    PubMed  CAS  Google Scholar 

  34. Otte C, Marmar CR, Pipkin SS et al (2004) Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 56:241–247

    PubMed  CAS  Google Scholar 

  35. Otte C, Neylan TC, Pipkin SS et al (2005) Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 162:2139–2145

    PubMed  Google Scholar 

  36. Schweiger U, Greggersen W, Rudolf S et al (2008) Disturbed glucose disposal in patients with major depression; application of the glucose clamp technique. Psychosom Med 70:170–176

    PubMed  Google Scholar 

  37. Whooley MA, Jonge P de, Vittinghoff E, Otte C et al (2008) Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300:2379–2388

    PubMed  CAS  Google Scholar 

  38. Win S, Parakh K, Eze-Nliam CM et al (2011) Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the Cardiovascular Health Study. Heart 97:500–505

    PubMed  Google Scholar 

  39. Gehi A, Haas D, Pipkin S, Whooley MA (2005) Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 165:2508–2513

    PubMed  Google Scholar 

  40. Thorndike AN, Regan S, McKool K et al (2008) Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med 168:186–191

    PubMed  Google Scholar 

  41. Glassman AH, O’Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709

    PubMed  CAS  Google Scholar 

  42. Lange-Asschenfeldt C, Lederbogen F (2011) Antidepressant therapy in coronary artery disease. Nervenarzt 82:657–664

    PubMed  CAS  Google Scholar 

  43. O’Connor CM, Jiang W, Kuchibhatla M et al (2008) Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 168:2232–2237

    Google Scholar 

  44. Taylor CB, Youngblood ME, Catellier D et al (2005) Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 62:792–798

    PubMed  CAS  Google Scholar 

  45. Honkola J, Hookana E, Malinen S et al (2012) Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 33:745–751

    PubMed  CAS  Google Scholar 

  46. Smoller JW, Allison M, Cochrane BB et al (2009) Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women’s Health Initiative study. Arch Intern Med 169:2128–2139

    PubMed  Google Scholar 

  47. Hamer M, David Batty G, Seldenrijk A, Kivimaki M (2011) Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 32:437–442

    PubMed  CAS  Google Scholar 

  48. Lichtman JH, Bigger JT Jr, Blumenthal JA et al (2008) Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 118:1768–1775

    PubMed  Google Scholar 

  49. Rijk MC de, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (Suppl 5):21–23

    Google Scholar 

  50. Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24:2175–2186

    PubMed  Google Scholar 

  51. Aarsland D, Ballard C, Walker Z et al (2009) Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613–618

    PubMed  CAS  Google Scholar 

  52. Seppi K, Weintraub D, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):42–80

    Google Scholar 

  53. Aarsland D, Påhlhagen S, Ballard CG et al (2011) Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47

    PubMed  Google Scholar 

  54. Reijnders JS, Ehrt U, Weber WE et al (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189

    PubMed  Google Scholar 

  55. Barone P et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    PubMed  Google Scholar 

  56. Riedel O, Dodel R, Deuschl G et al (2011) Dementia and depression determine care dependency in Parkinson’s disease: analysis of 1,449 outpatients receiving nursing care in Germany. Nervenarzt 82:1012–1019

    PubMed  CAS  Google Scholar 

  57. Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol Scand 113:211–220

    PubMed  CAS  Google Scholar 

  58. Schwarz J, Odin P, Buhmann C et al (2011) Depression in Parkinson’s disease. J Neurol 258 (Suppl 2):336–338

    Google Scholar 

  59. Nanhoe-Mahabier W et al (2009) Parkinson disease and comorbid cerebrovascular disease. Nat Rev Neurol 5:533–541

    PubMed  Google Scholar 

  60. Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580

    PubMed  CAS  Google Scholar 

  61. Skapinakis P et al (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10:49

    PubMed  Google Scholar 

  62. Richard IH, McDermott MP, Kurlan R et al (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78:1229–1236

    PubMed  CAS  Google Scholar 

  63. Weintraub D, Burn DJ (2011) Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 26:1022–1031

    PubMed  Google Scholar 

  64. Dobkin RD, Allen LA, Menza M (2007) Cognitive-behavioral therapy for depression in Parkinson’s disease: a pilot study. Mov Disord 22:946–952

    PubMed  Google Scholar 

  65. Farabaugh A et al (2010) Cognitive-behavioral therapy for patients with Parkinson’s disease and comorbid major depressive disorder. Psychosomatics 51:124–129

    PubMed  Google Scholar 

  66. Feinstein A (2006) Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci 245:63–66

    PubMed  Google Scholar 

  67. D’Alisa S, Miscio G, Baudo S et al (2006) Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study. Disabil Rehabil 28:307–314

    Google Scholar 

  68. Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 33:219–227

    PubMed  Google Scholar 

  69. Feinstein A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology 59:674–678

    PubMed  Google Scholar 

  70. Goldman (2005) The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 11:328–337

    Google Scholar 

  71. Siegert RJ, Abernethy DA (2005) Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 76:469–475

    PubMed  CAS  Google Scholar 

  72. Patten SB, Beck CA, Williams JV et al (2003) Major depression in multiple sclerosis: a population-based perspective. Neurology 61:1524–1527

    PubMed  CAS  Google Scholar 

  73. Schiffer RB, Wineman NM, Weitkamp LR (1986) Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 143:94–95

    PubMed  CAS  Google Scholar 

  74. Feinstein A (2011) Multiple sclerosis and depression. Mult Scler 17:1276–1281

    PubMed  Google Scholar 

  75. Feinstein A, O’Connor P, Feinstein K (2002) Multiple sclerosis, interferon beta-1b and depression. A prospective investigation. J Neurol 249:815–820

    PubMed  Google Scholar 

  76. Bakshi R, Czarnecki D, Shaikh ZA et al (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153–1158

    PubMed  CAS  Google Scholar 

  77. Bakshi R, Shaikh ZA, Miletich RS et al (2000) Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 6:181–185

    PubMed  CAS  Google Scholar 

  78. Feinstein A, Roy P, Lobaugh N et al (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62:586–590

    PubMed  CAS  Google Scholar 

  79. Zorzon M, Masi R de, Nasuelli D et al (2001) Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol 248:416–421

    PubMed  CAS  Google Scholar 

  80. Zorzon M, Zivadinov R, Nasuelli D et al (2002) Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 9:491–496

    PubMed  CAS  Google Scholar 

  81. Gold SM, Kern KC, O’Connor MF et al (2010) Smaller cornu ammonis 2–3 – dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry 68:553–559

    PubMed  CAS  Google Scholar 

  82. Kiy G, Lehmann P, Hahn HK et al (2011) Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler 17:1088–1097

    PubMed  Google Scholar 

  83. Fassbender K, Schmidt R, Mossner R et al (1998) Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol 55:66–72

    PubMed  CAS  Google Scholar 

  84. Gold SM, Kruger S, Ziegler KJ et al (2011) Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry 82:814–818

    PubMed  Google Scholar 

  85. Kern S, Schultheiss T, Schneider H et al (2011) Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. Psychoneuroendocrinology 36:1505–1512

    PubMed  CAS  Google Scholar 

  86. Pokryszko-Dragan A, Frydecka I, Kosmaczewska A et al (2012) Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg [Epub ahead of print]

  87. Fischer A, Otte C, Krieger T et al (2012) Decreased hydrocortisone sensitivity of T cell function in multiple sclerosis-associated major depression. Psychoneuroendocrinology [Epub ahead of print]

  88. Pakenham KI (1999) Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol 18:383–392

    PubMed  CAS  Google Scholar 

  89. Feinstein A (2005) The clinical neuropsychiatry of multiple sclerosis. CNS Spectr 10:362

    PubMed  Google Scholar 

  90. Koch MW, Glazenborg A, Uyttenboogaart M et al (2011) Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2:CD007295

    PubMed  Google Scholar 

  91. Mohr DC, Hart SL, Julian L et al (2005) Telephone-administered psychotherapy for depression. Arch Gen Psychiatry 62:1007–1014

    PubMed  Google Scholar 

  92. Grossman P, Kappos L, Gensicke H et al (2010) MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 75:1141–1149

    PubMed  CAS  Google Scholar 

  93. Mostert JP, Admiraal-Behloul F, Hoogduin JM et al (2008) Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry 79:1027–1031

    PubMed  CAS  Google Scholar 

  94. Sijens PE, Mostert JP, Irwan R et al (2008) Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Res 164:274–282

    PubMed  CAS  Google Scholar 

  95. Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151

    PubMed  Google Scholar 

  96. Stenager EN, Stenager E, Koch-Henrikson N et al (1992) Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry 55:542–545

    PubMed  CAS  Google Scholar 

  97. Stenager EN, Koch-Henriksen N, Stenager E (1996) Risk factors for suicide in multiple sclerosis. Psychother Psychosom 65:86–90

    PubMed  CAS  Google Scholar 

  98. Fuller-Thomson E, Brennenstuhl S (2009) The association between depression and epilepsy in a nationally representative sample. Epilepsia 50:1051–1058

    PubMed  Google Scholar 

  99. Mensah SA, Beavis JM, Thapar AK, Kerr MP (2007) A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav 11:118–124

    PubMed  Google Scholar 

  100. Canuet L, Ishii R, Iwase M et al (2009) Factors associated with impaired quality of life in younger and older adults with epilepsy. Epilepsy Res 83:58–65

    PubMed  Google Scholar 

  101. Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 170:205–228

    PubMed  CAS  Google Scholar 

  102. Nilsson L, Tomson T, Farahmand BY et al (1997) Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38:1062–1068

    PubMed  CAS  Google Scholar 

  103. Christensen J, Vestergaard M, Mortensen PB et al (2007) Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 6:693–698

    PubMed  Google Scholar 

  104. Bell GS, Sander JW (2009) Suicide and epilepsy. Curr Opin Neurol 22:174–178

    PubMed  Google Scholar 

  105. Hoppe C, Elger CE (2011) Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol 7:462–472

    PubMed  Google Scholar 

  106. Hermann BP, Trenerry MR, Colligan RC (1996) Learned helplessness, attributional style, and depression in epilepsy. Bozeman Epilepsy Surgery Consortium. Epilepsia 37:680–686

    PubMed  CAS  Google Scholar 

  107. Wagner JL, Smith G, Ferguson PL et al (2009) A hopelessness model of depressive symptoms in youth with epilepsy. J Pediatr Psychol 34:89–96

    PubMed  Google Scholar 

  108. Hesdorffer DC, Lee P (2009) Health, wealth, and culture as predominant factors in psychosocial morbidity. Epilepsy Behav 15:36–40

    Google Scholar 

  109. Sperling MR, Schilling CA, Glosser D et al (2008) Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. Seizure 17:302–307

    PubMed  Google Scholar 

  110. Kanner AM, Trimble M, Schmitz B (2010) Postictal affective episodes. Epilepsy Behav 19:156–158

    PubMed  Google Scholar 

  111. Hughes JR (2010) Periodic lateralized epileptiform discharges: do they represent an ictal pattern requiring treatment? Epilepsy Behav 18:162–165

    PubMed  Google Scholar 

  112. Mula M, Monaco F (2009) Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 11:1–9

    PubMed  Google Scholar 

  113. Miller JM, Kustra RP, Vuong A et al (2008) Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs 68:1493–1509

    PubMed  CAS  Google Scholar 

  114. Danzer SC (2012) Depression, stress, epilepsy and adult neurogenesis. Exp Neurol 233:22–32

    PubMed  Google Scholar 

  115. Micallef S, Spooner CG, Harvey AS et al (2010) Psychological outcome profiles in childhood-onset temporal lobe epilepsy. Epilepsia 51:2066–2073

    PubMed  Google Scholar 

  116. Barry JJ, Ettinger AB, Friel P et al (2008) Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav 13(Suppl 1):1–29

    Google Scholar 

  117. Bernardo CG, Singh V, Thompson PM (2008) Safety and efficacy of psychopharmacological agents used to treat the psychiatric sequelae of common neurological disorders. Expert Opin Drug Saf 7:435–445

    PubMed  CAS  Google Scholar 

  118. Ekinci O, Titus JB, Rodopman AA et al (2009) Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. Epilepsy Behav 14:8–18

    PubMed  Google Scholar 

  119. Thompson NJ et al (2010) Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav 19:247–254

    PubMed  Google Scholar 

  120. Walker ER, Obolensky N, Dini S, Thompson NJ (2010) Formative and process evaluations of a cognitive-behavioral therapy and mindfulness intervention for people with epilepsy and depression. Epilepsy Behav 19:239–246

    PubMed  Google Scholar 

  121. Ciechanowski P et al (2010) PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 19:225–231

    PubMed  Google Scholar 

  122. Wagner JL, Smith G, Ferguson P et al (2010) Pilot study of an integrated cognitive-behavioral and self-management intervention for youth with epilepsy and caregivers: Coping Openly and Personally with Epilepsy (COPE). Epilepsy Behav 18:280–285

    PubMed  Google Scholar 

  123. DiIorio C, Shafer PO, Letz R et al (2004) Project EASE study group. Project EASE: a study to test a psychosocial model of epilepsy medication managment. Epilepsy Behav 5:926–936

    PubMed  Google Scholar 

  124. Chaytor N, Ciechanowski P, Miller JW et al (2011) Long-term outcomes from the PEARLS randomized trial fort he treatment of depression in patients with epilepsy. Epilepsy Behav 20:545–549

    PubMed  Google Scholar 

  125. Lundgren T, Dahl J, Yardi N, Melin L (2008) Acceptance and commitment therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. Epilepsy Behav 13:102–108

    PubMed  Google Scholar 

  126. Lundgren T, Dahl J, Hayes SC (2008) Evaluation of mediators of change in the treatment of epilepsy with acceptance and commitment therapy. J Behav Med 31:225–235

    PubMed  Google Scholar 

  127. Martinovic Z, Simonovic P, Djokic R (2006) Preventing depression in adolescents with epilepsy. Epilepsy Behav 9:619–624

    PubMed  Google Scholar 

  128. Arida RM, Scorza FA, Cavalheiro EA (2010) Favorable effects of physical activity for recovery in temporal lobe epilepsy. Epilepsia 51:76–79

    PubMed  Google Scholar 

  129. Arida RM, Scorza FA, Silva SG da et al (2010) The potential role of physical exercise in the treatment of epilepsy. Epilepsy Behav 17:432–435

    PubMed  Google Scholar 

  130. Kanner AM (2011) Depression and epilepsy: a bidirectional relation? Epilepsia 52:21–27

    PubMed  Google Scholar 

  131. Cotterman-Hart S (2010) Depression in epilepsy: why aren’t we treating? Epilepsy Behav 19:419–421

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist für sich und seine Koautoren auf folgende Beziehungen hin: Christian Otte – Forschungsförderung: Roche, Beratungstätigkeit: Phineo, Vortragshonorare: Astra Zeneca, Berlin Chemie, Lundbeck, Servier; Matthias Endres – Forschungsförderung: AstraZeneca, Sanofi, Beratungstätigkeit: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Pfizer, Sanofi, Vortragshonorare: Astra Zeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb, Boehringer-Ingelheim, Desitin, Eisei, Ever, Glaxo Smith Kline, MSD, Novartis, Pfizer, Sanofi, Takeda, Trommsdorff.

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050, Berlin, Deutschland

    D. Piber, K. Hinkelmann & C Otte

  2. Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    S.M. Gold

  3. Klinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

    C. Heesen

  4. Asklepios Fachklinik Tiefenbrunn, Tiefenbrunn, Deutschland

    C. Spitzer

  5. Klinik für Neurologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    M. Endres

  6. Centrum für Schlaganfallforschung Berlin, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    M. Endres

  7. ExzellenzCluster NeuroCure, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland

    M. Endres & C Otte

Authors
  1. D. Piber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Hinkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S.M. Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Heesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Spitzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Endres
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Otte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Piber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piber, D., Hinkelmann, K., Gold, S. et al. Depression und neurologische Erkrankungen. Nervenarzt 83, 1423–1433 (2012). https://doi.org/10.1007/s00115-012-3674-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-012-3674-7

Schlüsselwörter

Keywords

Search

Navigation